Toggle Main Menu Toggle Search

Open Access padlockePrints

Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19–related illness

Lookup NU author(s): Dr Tina Biss

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

© 2020 International Society on Thrombosis and HaemostasisBackground: Observational studies indicate that children hospitalized with COVID-19-related illness, like adults, are at increased risk for venous thromboembolism (VTE). A multicenter phase 2 clinical trial of anticoagulant thromboprophylaxis in children hospitalized with COVID-19-related illness has recently been initiated in the United States. To date, there remains a paucity of high-quality evidence to inform clinical practice world-wide. Therefore, the objective of this scientific statement is to provide consensus-based recommendations on the use of anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illnesses, and to identify priorities for future research. Methods: We surveyed 20 pediatric hematologists and pediatric critical care physicians from several continents who were identified by Pediatric/Neonatal Hemostasis and Thrombosis Subcommittee leadership as having experience and expertise in the use of anticoagulant thromboprophylaxis and/or the management of COVID-19-related illness in children. A comprehensive review of the literature on COVID-19 in children was also performed. Results: Response rate was 90%. Based on consensus of expert opinions, we suggest the administration of low-dose low molecular weight heparin subcutaneously twice-daily as anticoagulant thromboprophylaxis (in the absence of contraindications, and in combination with mechanical thromboprophylaxis with sequential compression devices, where feasible) in children hospitalized for COVID-19-related illness (including the multisystem inflammatory syndrome in children [MIS-C]) who have markedly elevated D-dimer levels or superimposed clinical risk factors for hospitalassociated VTE. For children who are clinically unstable or have severe renal impairment, we suggest the use of unfractionated heparin by continuous intravenous infusion as anticoagulant thromboprophylaxis. In addition, continued efforts to characterize VTE risk and risk factors in children with COVID-19, as well as to evaluate the safety and efficacy of anticoagulant thromboprophylaxis strategies in children hospitalized with COVID-19-related illness (including MIS-C) via cooperative multicenter trials, were identified among several key priorities for future research. Conclusion: These consensus-based recommendations on the use of anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illnesses and priorities for future research will be updated as high-quality evidence emerges.


Publication metadata

Author(s): Goldenberg NA, Sochet A, Albisetti M, Biss T, Bonduel M, Jaffray J, MacLaren G, Monagle P, O'Brien S, Raffini L, Revel-Vilk S, Sirachainan N, Williams S, Zia A, Male C

Publication type: Article

Publication status: Published

Journal: Journal of Thrombosis and Haemostasis

Year: 2020

Volume: 18

Issue: 11

Pages: 3099-3105

Print publication date: 01/11/2020

Online publication date: 28/08/2020

Acceptance date: 20/08/2020

ISSN (print): 1538-7933

ISSN (electronic): 1538-7836

Publisher: Blackwell Publishing Ltd

URL: https://doi.org/10.1111/jth.15073

DOI: 10.1111/jth.15073


Altmetrics

Altmetrics provided by Altmetric


Share